Yarrow Bioscience
YARW
97 hedge funds and large institutions have $132M invested in Yarrow Bioscience in 2020 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 19 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
1% less funds holding
Funds holding: 98 → 97 (-1)
2.57% less ownership
Funds ownership: 50.09% → 47.52% (-2.6%)
17% less capital invested
Capital invested by funds: $160M → $132M (-$27.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.64M |
| 2 |
State Street
Boston,
Massachusetts
|
+$747K |
| 3 |
6CM
683 Capital Management
New York
|
+$677K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$595K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$443K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$2.95M |
| 2 |
Millennium Management
New York
|
-$2.15M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$2.05M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$1.26M |
| 5 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
-$1.12M |
YARW Hedge Fund Activity: Q3 2020 in Review
97 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience (YARW) for Q3 2020, worth a combined $132M — down 17% from $160M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of YARW and 18 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 31 added.
The largest buyer was BlackRock, adding an estimated $2.64M. The largest seller was Vivo Capital, cutting an estimated $2.95M.
- 97 institutional investors held Yarrow Bioscience (YARW) as of Q3 2020, down from 98 in Q2 2020.
- Funds reported $132M of Yarrow Bioscience stock for Q3 2020, down 17% quarter-over-quarter.
- 18 funds opened new Yarrow Bioscience positions in Q3 2020 and 19 closed out, a net change of -1 holder.
- The largest Yarrow Bioscience buyer in Q3 2020 was BlackRock, an estimated $2.64M added.
- The largest Yarrow Bioscience seller in Q3 2020 was Vivo Capital, an estimated $2.95M sold.
Based on aggregated 13F filings for Q3 2020.